TSRI-Designed Drug Candidate Significantly Reduces HIV Reactivation Rate
Chemists Develop Efficient, Scalable Synthesis of Potential Brain-Protecting Compound
Small RNAs Found to Play Important Roles in Memory Formation
Best-Selling Author Launches Second Fundraising Effort for Alzheimer’s Research
Scientists Win $1.2M to Study Environmental Triggers of Lupus, Rheumatoid Arthritis
Snapshot: Research Associate Arryn Craney



Chemists Develop Efficient, Scalable Synthesis of Potential Brain-Protecting Compound

Chemists at The Scripps Research Institute (TSRI) have invented the first practical, scalable method for synthesizing jiadifenolide, a plant-derived molecule that may have powerful brain-protecting properties.

Finding a good way to synthesize jiadifenolide has been a goal of chemists around the world since the compound was discovered in 2009. Preliminary studies have hinted that it might be useful in protecting brain cells from neurodegenerative diseases such as Alzheimer’s and perhaps other neurological conditions including stroke and traumatic brain injury. But it is very difficult to obtain useful quantities of jiadifenolide from plants, and the synthesis methods reported in the past few years also have low yields.

“Prior synthetic routes to jiadifenolide yield a few milligrams, suitable mainly for cell-culture experiments, but with our new method someone could make the gram to kilogram quantities needed for tests in animals and humans,” said Ryan A. Shenvi, associate professor at TSRI.

shenvi group
Authors of the new Nature Chemistry study include (left to right) Research Associate Hai-Hua Lu, Associate Professor Ryan Shenvi and Graduate Student Michael Martinez. (Photo by Cindy Brauer.)

The feat by Shenvi and his team, described recently in an Advance Online Publication in Nature Chemistry, may therefore lead to the development, years from now, of a jiadifenolide-derived drug.

The achievement also demonstrates the increasing power of synthetic chemistry to produce the potentially valuable molecules found in nature on large scale at low cost.

“There are more and more examples these days of syntheses that start with cheap, readily available chemicals and assemble them into complex and valuable molecules on a meaningful scale—much more efficiently than if you tried to isolate the molecules from nature or produce them in genetically engineered organisms,” said Shenvi.

A Tantalizing Target

Jiadifenolide is found in trace quantities in the fruit of the star anise-related shrub Illicium jiadifengpi, which grows in southern China. It and other Illicium plants have long featured in Chinese traditional medicine. Most parts of I. jiadifengpi are poisonous if eaten, but root extracts applied to the skin have been used to treat arthritis.

In 2009, a team of Japanese and Chinese scientists reported isolating tiny quantities of jiadifenolide from I. jiadifengpi. They determined that the compound, unlike many others from the plant, is not toxic, and indeed strongly promotes the growth of axons and dendrites (output and input branches) from rat neurons in a culture dish. Subsequent research has suggested that jiadifenolide works by enhancing the activity of natural brain growth factors, known as neurotrophins.

“Neurotrophin levels are depressed in diseases like Alzheimer’s, so researchers have long sought compounds that behave like neurotrophins or that amplify their activity, especially those that could be taken in a pill,” said Shenvi.

Neurotrophins themselves are large molecules that effectively can’t be used as drugs, because they are rapidly broken down by enzymes in the digestive tract and bloodstream and also don’t cross the blood-brain barrier easily. Jiadifenolide by contrast is a small molecule, and thus has more potential to be developed into an oral drug.

‘A Completely Different Approach’

Shenvi’s laboratory took up the jiadifenolide synthesis challenge a few years after the first, low-yield method was reported in 2011. “While we worked on this, two other groups reported their own synthetic routes, which pushed us to find a completely different approach,” said Hai-Hua Lu, a research associate in the Shenvi laboratory who was lead author of the new study.

The new, eight-step synthesis involves merging two simple molecules, called butenolides, via a process called the Michael reaction—in fact, a double Michael reaction—to make a compound very close to jiadifenolide itself.

“It’s a chemical reaction that few people (myself included) would have confidently predicted to work,” Shenvi said.

“After we figured out how to do that, though, the rest was much easier and we found we could obtain more than a gram from one batch,” said Lu.

Now that jiadifenolide can be produced in sufficient quantities, Shenvi is looking for companies that can help with further studies of the compound, including tests in animal models of neurodegenerative diseases.

Shenvi also suspects that the new method can be adapted for the practical synthesis of related trace compounds found in Illicium plants.

He admits, though, that it is not just the therapeutic potential of this plant metabolite that has attracted him and other synthetic chemists.

“The peculiar geometry of jiadofenolide lends it a certain beauty, like a geodesic dome or a mosaic tessellation. It’s the combination of structural beauty, chemical challenge and therapeutic potential that has stimulated so much interest,” he said.

The other author of the paper, “An eight-step gram-scale synthesis of (−)-jiadifenolide,” was National Science Foundation (NSF) pre-doctoral fellow Michael D. Martinez, a second-year graduate student in the Shenvi laboratory. “Many related Illicium sesquiterpenes also demonstrate neurotrophic properties and share a common structural core with (-)-jiadifenolide,” said Martinez. “Our route to access (-)-jiadifenolide may provide inroads to these related natural products and analogues.” See

The research was funded in part by the NSF (DGE-1346837), as well as Amgen, Boehringer Ingelheim, the Baxter Foundation, Bristol-Myers Squibb, Eli Lilly, Novartis and the Sloan Foundation.

Send comments to: press[at]